Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow COLLEGIUM PHARMACEUTICAL, INC

Get SEC filing alerts via email and in your feed for COLLEGIUM PHARMACEUTICAL, INC

COLL

COLLEGIUM PHARMACEUTICAL, INC

About COLLEGIUM PHARMACEUTICAL, INC

Collegium Pharmaceutical is a biopharmaceutical company focused on developing and commercializing differentiated products for serious medical conditions, including pain management and ADHD. Its portfolio features abuse-deterrent opioids, ADHD stimulants, and treatments for opioid-induced constipation. The company emphasizes innovative formulations, regulatory compliance, and intellectual property protection, serving healthcare providers and patients in the U.S. through a direct sales force and strategic licensing agreements.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from COLLEGIUM PHARMACEUTICAL, INC

1
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 9% Revenue Growth and Strategic Acquisition in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 24% Revenue Growth to $780.6 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 31.4% Revenue Growth to $209.4 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 29% Revenue Growth in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 22.7% Revenue Growth to $177.8 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports $631.4M Revenue for Fiscal Year 2024, Driven by Jornay Sales

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
COLLEGIUM PHARMACEUTICAL, INC Collegium Pharmaceutical Reports 16.5% Revenue Growth, Net Income Decline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments